RxDoctor Payments Data

Edison Ong, MD

Family Medicine · Abbeville, LANPI 1598794406

Payments from drug & device makers

$2,556in general payments, 2019–2025

Across 112 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$578
  • AbbVie$294
  • Ironshore Pharmaceuticals Inc.$165
  • Sanofi-aventis U.S. LLC$150
  • Amgen$132
  • Indivior Inc.$130
  • plus $1K from 21 others

What the payments were for

  • Speaking & faculty fees$1506%
  • Food & beverage$2,40694%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,556 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$370
Medicare patients
11
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$91,923
JardianceEmpagliflozin56$62,750
FarxigaDapagliflozin Propanediol70$54,867
KevzaraSarilumab11$44,882
TradjentaLinagliptin44$39,435
LinzessLinaclotide46$35,390
JanumetSitagliptin Phos/Metformin Hcl13$16,228
MounjaroTirzepatide15$14,950
EliquisApixaban23$13,587
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$12,535
Novolog FlexpenInsulin Aspart18$8,213
SymbicortBudesonide/Formoterol Fumarate26$5,802
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$5,605
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen526$4,304
Albuterol Sulfate HfaAlbuterol Sulfate155$4,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$16$102,185100 claims
AstraZenecaFarxiga, Symbicort$64$60,66996 claims
AbbVieLinzess$294$35,39046 claims
Lilly USA, LLCMounjaro$87$14,95015 claims
PfizerEliquis$101$13,58723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Abbeville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →